Credit Analysis and Research (CARERATING) is the subject of this data-driven review, spanning financial performance, valuation, and shareholding trends.
Care Rating Revenue Trend
For FY2026, Credit Analysis and Research posted revenue of ₹473 Cr, up 17.6% from FY2025.
Revenue for Credit Analysis and Research has compounded at 5.4% annually over 10 years. That's a reasonable growth rate, roughly in line with the broader market.
With a ₹473 Cr revenue base, Credit Analysis and Research sits in the smaller bracket among rating agencies companies in India.
What stands out is the consistency: top-line revenue has grown for 4 consecutive years.
| Year | Revenue | YoY % |
|---|---|---|
| FY2026 | ₹473 Cr | +17.6% |
| FY2025 | ₹402 Cr | +21.3% |
| FY2024 | ₹332 Cr | +18.9% |
| FY2023 | ₹279 Cr | +12.7% |
| FY2022 | ₹248 Cr | — |
View Credit Analysis and Research's full 10-year revenue trend with CAGR analysis →
Care Rating Profitability
Net profit came in at ₹174 Cr in FY2026 for Credit Analysis and Research, a solid 24.1% jump from ₹140 Cr in FY2025.
Margins improved too: net margin went from 34.8% in FY2025 to 36.7% in FY2026.
Diluted EPS came in at ₹56.83 in FY2026, versus ₹45.69 in FY2025.
Is Care Rating Undervalued
Shares of Credit Analysis and Research currently trade at ₹1,715.60.
Craytheon calculates intrinsic value using the P/E Ratio, DCF, and EPS Growth models. All three appear in the Valuation Models cards below.
Valuation Models
Care Rating Shareholding Pattern
Credit Analysis and Research is widely held, with no promoter group. Ownership is spread across institutional and public shareholders.
As of June 2026, foreign institutional investors (FIIs) held 23.4%, down from 23.6% a year earlier.
Domestic institutional investors (DIIs) held 31.6% as of June 2026, down from 31.6% a year ago.
| Quarter | Promoter | FII | DII | Public |
|---|---|---|---|---|
| Jun 2026 | 0.0% | 23.4% | 31.6% | 45.0% |
| Mar 2026 | 0.0% | 23.2% | 31.4% | 45.4% |
| Dec 2025 | 0.0% | 23.0% | 31.3% | 45.7% |
| Sep 2025 | 0.0% | 23.6% | 31.6% | 44.8% |
Track quarterly shareholding changes for Credit Analysis and Research →
Care Rating Balance Sheet
Proportional view as of 3 Aug 2026. Hover blocks for details.
Assets
Liabilities & Equity
FY2026 total assets: ₹11.05B (up 15.3% YoY from ₹9.58B).
Top categories: Other Assets (76.1%), Property, Plant & Equipment (7.4%), Investments (6.0%).
Of the ₹11.05B in liabilities and equity, 85.4% is shareholder equity, 2.4% is interest-bearing debt, and 12.3% is operating liabilities. Over the year, debt is up 10.2% and equity is up 15.6%.
Balance sheet composition — FY 2026
| Category | Value |
|---|---|
| Cash & ST Investments | 631.35M |
| Receivables | 350.35M |
| Property, Plant & Equipment | 813.27M |
| Investments | 663.43M |
| Intangibles & Goodwill | 179.14M |
| Other Assets | 8.41B |
| Category | Value |
|---|---|
| Equity | 9.43B |
| Short-term Debt | 43.80M |
| Long-term Debt | 218.05M |
| Trade Payables | 148.94M |
| Other Liabilities | 1.21B |
Care Rating at a Glance
Based on the latest available financials, here's the bottom line on Credit Analysis and Research (CARERATING).
FY2026 revenue of ₹473 Cr, up 17.6% year-over-year.
Over 10 years, revenue has compounded at 5.4% annually.
Profitability is solid: net margin of 36.7% and net income of ₹174 Cr.
Unlock Full Analysis
Craytheon's full analysis of Credit Analysis and Research goes deeper: three valuation models, growth metrics, and 10 years of financial data.